COVID-19 Prevention and Treatment Strategies for the Immunocompromised-Living Handout
|Content Release Date: 7/19/2022
Expiration Date: 7/19/2023
CE Credits: NONE
Activity Fee: Free
Vaccination is the most effective method to prevent COVID-19, and death rates worldwide are highest among people who are unvaccinated. Although the push to get Americans vaccinated against COVID-19 is ongoing, patients with compromised immune systems remain a challenge. There are roughly 7 million immunocompromised adults in the U.S., which includes those who have had organ transplants, stem cell transplants, and cancer as well as those with primary immunodeficiency and those treated with immunosuppressive medications. Newer monoclonal antibodies may be successful in preventing SARS-CoV-2 infection as an alternative to vaccination for people who cannot take a vaccine or need immediate prophylaxis before or after exposure.
There is NO CE with this activity.
This handout will be updated regularly throughout the year.
CE Credits: none
Engaging the Experts Podcasts
New Year, New Subvariants - COVID Therapeutics in 2023
Podcast 3:COVID Updates and the End of PHE: What it Means for You
|CE Credits: none|
The target audience for these educational activities is pharmacists who practice in hospitals and health systems who care for or are interested in the treatment of patients at risk for COVID-19, particularly the immunocompromised.
Katherine Yang, PharmD, MPH, FCSHP
Health Sciences Clinical Professor of Pharmacy
University of California, San Francisco (UCSF) School of Pharmacy
Infectious Diseases Clinical Pharmacist
UCSF Medical Center
San Francisco, California
Katherine Yang, PharmD, MPH, FCSHP is a Health Sciences Clinical Professor of Pharmacy at the UCSF School of Pharmacy and an infectious diseases clinical pharmacist at the UCSF Medical Center in San Francisco, California. Dr. Yang specializes in the pharmacokinetic and pharmacodynamic optimization of antibiotic dosing for the treatment of multi-drug resistant gram-negative infections. Since the start of the pandemic, Dr. Yang has been heavily involved in the management of COVID-19 therapeutics.
Monica V. Mahoney PharmD, BCPS, BCIDP, FCCP
Clinical Pharmacy Specialist, Infectious Diseases
Outpatient ID/OPAT Clinics
Beth Israel Deaconess Medical Center
Monica Mahoney, PharmD, BCPS, BCIDP, FCCP is a clinical pharmacy specialist in the outpatient infectious diseases and outpatient parenteral antibiotic therapy clinics at Beth Israel Deaconess Medical Center. Dr. Mahoney received her PharmD degree from Massachusetts College of Pharmacy and Health Sciences in Boston, Massachusetts. She completed postgraduate year 1 residency and postgraduate year 2 infectious diseases residency at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, the Society of Infectious Diseases Pharmacists, and the Infectious Diseases Society of America.
Michael Ganio, Pharm.D., M.S., BCPS, FASHP
Senior Director, Pharmacy Practice and Quality
Dr. Ganio joined the staff at ASHP as Director of Pharmacy Practice and Quality in January of 2018. As a member of the Center on Medication Safety and Quality team, his responsibilities span the practice of pharmacy and include drug shortages, pharmaceutical quality, sterile and non-sterile drug compounding practices, hazardous drug handling, and the ASHP Standardize 4 Safety initiative. Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master’s degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center. Dr. Ganio is a Board Certified Pharmacotherapy Specialist (BCPS) and is a Certified Professional in Healthcare Information and Management Systems (CPHIMS).
Relevant Financial Relationship Disclosures
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.
Provided by ASHP.
Supported by an educational grant from AstraZeneca.